

## Highly Potent HIV-1 Protease Inhibitors

**A new class of highly potent protease inhibitors offers an improved treatment option for multidrug-resistant HIV-1, outperforming a leading FDA-approved drug by 100 times in cell culture.**

There is a need to develop new treatments for patients living with HIV-1, as HIV-1 rapidly acquires resistance to treatment options. Researchers at Purdue University have developed a new class of HIV-1 protease inhibitors. Compared to darunavir, a leading FDA approved drug, these compounds were 100 times more potent in cell culture. Additionally, the compounds have improved metabolic stability over previous protease inhibitors. The primary application for these compounds is for the treatment of multidrug-resistant HIV-1.

### Advantages:

- Improved potency against HIV-1
- Improved pharmacokinetic properties

### Potential Applications:

- HIV/AIDS treatment

Publication: Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities

ACS Med. Chem. Lett. 2020, 11, 1965~1972

<https://doi.org/10.1021/acsmchemlett.9b00670>

**TRL:** 3

### Intellectual Property:

Provisional-Patent, 2019-01-15, United States | NATL-Patent, 2020-01-15, Europe | PCT-Gov. Funding, 2020-01-15, WO | NATL-Patent, 2021-07-15, United States | NATL-Patent, N/A, Europe

Explore other available products test at [The Office of Technology Commercialization Online Licensing Store](#)

### Technology ID

2019-GHOS-68467

### Category

Pharmaceuticals/Other

### Authors

Arun K Ghosh  
Hiroaki Mitsuya

### Further information

Joe Kasper  
[JKKasper@prf.org](mailto:JKKasper@prf.org)

Nathan Smith  
[nesmith@prf.org](mailto:nesmith@prf.org)

### View online

